Decentralized Clinical Trials (DCTs) 2.0
By 2026, Decentralized and Hybrid trials have evolved from experimental pilots into the industry-standard expectation.
Global Patient Reach: DCT models are projected to grow by 15–20% this year, enabling CROs to recruit diverse populations across continents who were previously inaccessible.
Digital Biomarkers: Wearables and remote monitoring tools now provide continuous, real-time data capture, reducing the reliance on infrequent in-person site visits.
Retention & Adherence: Telemedicine and digital portals have significantly reduced dropout rates by making participation more convenient for patients, particularly in chronic and rare disease categories.
1 View